Jing Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jing Gao has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Feiyu Wang
Department of Neurology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China
3 shared publicationsHailin Yang
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, 266100, Shandong Province, China
3 shared publicationsRujie Zhong
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, 266100, Shandong Province, China
3 shared publicationsTao Liu
Department of Neurology, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
3 shared publicationsXiaoyu Li
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, 266100, Shandong Province, China
3 shared publications- Anmu Xie
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China
2 shared publications
Latest Publications
- 13 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Inhibition of aerobic glycolysis suppresses ferroptosis via activation of the AMPK–FoxO3a pathway in epileptic rats
Ferroptosis has recently been implicated in seizure-induced neurodegeneration, whereas enhanced aerobic glycolysis during seizures may aggravate oxidative stress and ferroptotic damage. This study investigated whether inhibition of aerobic glycolysis suppresses ferroptosis through activation of the AMP-activated protein kinase (AMPK)-Forkhead box O3a (FoxO3a) signaling pathway in epileptic rats. A pilocarpine (PILO)-induced epilepsy model was established in male Wistar rats. Animals were treated with the aerobic glycolysis inhibitor 2-deoxy-D-glucose (2-DG), with or without the AMPK inhibitor Compound C. Behavioral evaluation, Morris water maze testing, biochemical assays, immunohistochemistry, quantitative real-time PCR, western blotting, and mitochondrial membrane potential analyses were performed. Epileptic rats exhibited significant upregulation of pyruvate kinase M2 (PKM2), pyruvate dehydrogenase kinase 1 (PDK1), and lactate dehydrogenase A (LDHA), indicating enhanced aerobic glycolysis in the hippocampus. Treatment with 2-DG significantly reduced seizure severity and improved spatial learning and memory. Moreover, inhibition of aerobic glycolysis markedly decreased Fe²⁺ and malondialdehyde (MDA) accumulation, restored glutathione (GSH) and glutathione peroxidase 4 (Gpx4) levels, preserved mitochondrial membrane potential, and enhanced AMPK and FoxO3a activation. These protective effects were substantially reversed by Compound C administration. Inhibition of aerobic glycolysis attenuates seizure-induced ferroptosis through activation of the AMPK-FoxO3a pathway. These findings establish a mechanistic link between metabolic reprogramming and ferroptosis in epilepsy and suggest that targeting aerobic glycolysis may represent a promising therapeutic strategy for neuroprotection in epilepsy.
- 13 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Inhibition of aerobic glycolysis suppresses ferroptosis via activation of the AMPK–FoxO3a pathway in epileptic rats
Ferroptosis has recently been implicated in seizure-induced neurodegeneration, whereas enhanced aerobic glycolysis during seizures may aggravate oxidative stress and ferroptotic damage. This study investigated whether inhibition of aerobic glycolysis suppresses ferroptosis through activation of the AMP-activated protein kinase (AMPK)-Forkhead box O3a (FoxO3a) signaling pathway in epileptic rats. A pilocarpine (PILO)-induced epilepsy model was established in male Wistar rats. Animals were treated with the aerobic glycolysis inhibitor 2-deoxy-D-glucose (2-DG), with or without the AMPK inhibitor Compound C. Behavioral evaluation, Morris water maze testing, biochemical assays, immunohistochemistry, quantitative real-time PCR, western blotting, and mitochondrial membrane potential analyses were performed. Epileptic rats exhibited significant upregulation of pyruvate kinase M2 (PKM2), pyruvate dehydrogenase kinase 1 (PDK1), and lactate dehydrogenase A (LDHA), indicating enhanced aerobic glycolysis in the hippocampus. Treatment with 2-DG significantly reduced seizure severity and improved spatial learning and memory. Moreover, inhibition of aerobic glycolysis markedly decreased Fe²⁺ and malondialdehyde (MDA) accumulation, restored glutathione (GSH) and glutathione peroxidase 4 (Gpx4) levels, preserved mitochondrial membrane potential, and enhanced AMPK and FoxO3a activation. These protective effects were substantially reversed by Compound C administration. Inhibition of aerobic glycolysis attenuates seizure-induced ferroptosis through activation of the AMPK-FoxO3a pathway. These findings establish a mechanistic link between metabolic reprogramming and ferroptosis in epilepsy and suggest that targeting aerobic glycolysis may represent a promising therapeutic strategy for neuroprotection in epilepsy.
- Open Access
- 12 March 2026
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 23 (1)
Association between monounsaturated fatty acids intake with Parkinson’s disease: a cross-sectional study
To investigate the association between monounsaturated fatty acids (MUFAs) intake and the prevalence of Parkinson’s disease (PD) among US adults usin
- 12 March 2026
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 23 (1)
Open AccessAssociation between monounsaturated fatty acids intake with Parkinson’s disease: a cross-sectional study
To investigate the association between monounsaturated fatty acids (MUFAs) intake and the prevalence of Parkinson’s disease (PD) among US adults usin
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-25
A Single-Cell Transcriptomic Atlas Elucidates a Microglial Gene Signature Linking Ferroptosis to Mitochondrial Dysfunction in Epilepsy
Epilepsy is a chronic neurological disorder caused by abnormal synchronous discharges of neurons, with ferroptosis and mitochondrial dysfunction implicated in its progression. However, a lack of resolution at the level of specific cell types has obscured critical roles and molecular mechanisms within the epileptic microenvironment. This study integrated single-nucleus RNA sequencing (snRNA-seq) and bulk RNA-seq data from epilepsy and control samples. We performed dimensionality reduction and clustering to identify 13 cell subpopulations, and then assessed the expression of ferroptosis-related genes (FRGs) and mitochondrial-related genes (MRGs) within 7 major cell types. Three machine learning algorithms were further applied to identify key genes in microglia. Subsequent analyses included immune infiltration, pathway enrichment, and drug–target interaction. Molecular docking and molecular dynamics simulations were used to evaluate the potential binding affinity of the predicted drug. In vivo validation included histopathology, mitochondrial electron microscopy, JC-1 staining, and immunohistochemistry (IHC). We identified six key genes (ATM, TGFBR1, ZEB1, PARP14, GJA1, and ALOX5), which link ferroptosis and mitochondrial dysfunction with a central role for microglia in epilepsy. These genes were associated with immune infiltration, including increased Th1 cell levels and reduced CD8+ T cell abundance. Enrichment analyses implicated these hub genes in orchestrating key epileptogenic processes, including neuroinflammatory pathways, ferroptosis, and interferon response. PARP14 was upregulated in epileptic rats, and GJA1 exhibited stable binding with bleomycin. Histopathological and mitochondrial assays confirmed the presence of ferroptosis and mitochondrial damage in epilepsy. This study highlights the interplay between ferroptosis and mitochondrial dysfunction in epilepsy, identifying six key microglial genes as high-priority candidates for future mechanistic and therapeutic investigation. Notably, PARP14 is implicated in epileptogenesis for the first time. The stable binding between GJA1 and bleomycin offers a novel avenue for epilepsy treatment, warranting further experimental validation.
- 1 January 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-25
Open AccessA Single-Cell Transcriptomic Atlas Elucidates a Microglial Gene Signature Linking Ferroptosis to Mitochondrial Dysfunction in Epilepsy
Epilepsy is a chronic neurological disorder caused by abnormal synchronous discharges of neurons, with ferroptosis and mitochondrial dysfunction implicated in its progression. However, a lack of resolution at the level of specific cell types has obscured critical roles and molecular mechanisms within the epileptic microenvironment. This study integrated single-nucleus RNA sequencing (snRNA-seq) and bulk RNA-seq data from epilepsy and control samples. We performed dimensionality reduction and clustering to identify 13 cell subpopulations, and then assessed the expression of ferroptosis-related genes (FRGs) and mitochondrial-related genes (MRGs) within 7 major cell types. Three machine learning algorithms were further applied to identify key genes in microglia. Subsequent analyses included immune infiltration, pathway enrichment, and drug–target interaction. Molecular docking and molecular dynamics simulations were used to evaluate the potential binding affinity of the predicted drug. In vivo validation included histopathology, mitochondrial electron microscopy, JC-1 staining, and immunohistochemistry (IHC). We identified six key genes (ATM, TGFBR1, ZEB1, PARP14, GJA1, and ALOX5), which link ferroptosis and mitochondrial dysfunction with a central role for microglia in epilepsy. These genes were associated with immune infiltration, including increased Th1 cell levels and reduced CD8+ T cell abundance. Enrichment analyses implicated these hub genes in orchestrating key epileptogenic processes, including neuroinflammatory pathways, ferroptosis, and interferon response. PARP14 was upregulated in epileptic rats, and GJA1 exhibited stable binding with bleomycin. Histopathological and mitochondrial assays confirmed the presence of ferroptosis and mitochondrial damage in epilepsy. This study highlights the interplay between ferroptosis and mitochondrial dysfunction in epilepsy, identifying six key microglial genes as high-priority candidates for future mechanistic and therapeutic investigation. Notably, PARP14 is implicated in epileptogenesis for the first time. The stable binding between GJA1 and bleomycin offers a novel avenue for epilepsy treatment, warranting further experimental validation.
- 10 November 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (6) , 1-19
Mitochondria-Mediated Mechanisms of Ferroptosis in Neurological Diseases
Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, is increasingly recognized as a critical contributor to the pathogenesis of various neurological disorders. Mitochondria, the powerhouses of cells, play dual roles as both initiators and mediators of ferroptosis by integrating lipid peroxidation cascades, oxidative stress responses, and iron homeostasis dysregulation. This review first comprehensively explores the multifaceted mechanisms by which mitochondria mediate ferroptosis in neurological diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Friedreich’s ataxia (FRDA), amyotrophic lateral sclerosis (ALS), epilepsy, stroke, and brain injury, with a focus on mitochondrial lipid peroxidation and iron metabolism dysregulation. Building on these mechanistic insights, we further discuss emerging evidence suggesting that targeting mitochondrial pathways may represent a promising therapeutic strategy for mitigating ferroptosis-associated neuronal damage. By synthesizing these findings, our review establishes a conceptual foundation for developing innovative neuroprotective interventions through precise modulation of mitochondrial function within ferroptotic pathways.
- 10 November 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (6) , 1-19
Mitochondria-Mediated Mechanisms of Ferroptosis in Neurological Diseases
Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, is increasingly recognized as a critical contributor to the pathogenesis of various neurological disorders. Mitochondria, the powerhouses of cells, play dual roles as both initiators and mediators of ferroptosis by integrating lipid peroxidation cascades, oxidative stress responses, and iron homeostasis dysregulation. This review first comprehensively explores the multifaceted mechanisms by which mitochondria mediate ferroptosis in neurological diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Friedreich’s ataxia (FRDA), amyotrophic lateral sclerosis (ALS), epilepsy, stroke, and brain injury, with a focus on mitochondrial lipid peroxidation and iron metabolism dysregulation. Building on these mechanistic insights, we further discuss emerging evidence suggesting that targeting mitochondrial pathways may represent a promising therapeutic strategy for mitigating ferroptosis-associated neuronal damage. By synthesizing these findings, our review establishes a conceptual foundation for developing innovative neuroprotective interventions through precise modulation of mitochondrial function within ferroptotic pathways.
- 21 March 2024
- Published by Elsevier in Brain Research
- Vol. 1836, 148882
Mitochondria-targeting peptide SS-31 attenuates ferroptosis via inhibition of the p38 MAPK signaling pathway in the hippocampus of epileptic rats
- 21 March 2024
- Published by Elsevier in Brain Research
- Vol. 1836, 148882
Mitochondria-targeting peptide SS-31 attenuates ferroptosis via inhibition of the p38 MAPK signaling pathway in the hippocampus of epileptic rats
- 29 March 2023
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 34 (6) , 368-374
Activation of PPARγ prevents ferroptosis-induced damage through Nrf2/Gpx4 signaling pathway in rat hippocampus following epilepsy
- 29 March 2023
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 34 (6) , 368-374
Activation of PPARγ prevents ferroptosis-induced damage through Nrf2/Gpx4 signaling pathway in rat hippocampus following epilepsy
- 1 March 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 747, 135614
Role of ferroptosis in neurological diseases
- 1 March 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 747, 135614
Role of ferroptosis in neurological diseases
- Open Access
- 18 June 2019
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 13, 552
Prion-Like Mechanisms in Parkinson’s Disease
Formation and aggregation of misfolded proteins in the central nervous system (CNS) is a key hallmark of several age-related neurodegenerative diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS). These diseases share key biophysical and biochemical characteristics with prion diseases. It is believed that PD is characterized by abnormal protein aggregation, mainly that of α-synuclein (α-syn). Of particular importance, there is growing evidence indicating that abnormal α-syn can spread to neighboring brain regions and cause aggregation of endogenous α-syn in these regions as seeds, in a “prion-like” manner. Abundant studies in vitro and in vivo have shown that α-syn goes through a templated conformational change, propagates from the original region to neighboring regions, and eventually cause neuron degeneration in the substantia nigra and striatum. The objective of this review is to summarize the mechanisms involved in the aggregation of abnormal intracellular α-syn and its subsequent cell-to-cell transmission. According to these findings, we look forward to effective therapeutic perspectives that can block the progression of neurodegenerative diseases.
- 18 June 2019
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 13, 552
Open AccessPrion-Like Mechanisms in Parkinson’s Disease
Formation and aggregation of misfolded proteins in the central nervous system (CNS) is a key hallmark of several age-related neurodegenerative diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS). These diseases share key biophysical and biochemical characteristics with prion diseases. It is believed that PD is characterized by abnormal protein aggregation, mainly that of α-synuclein (α-syn). Of particular importance, there is growing evidence indicating that abnormal α-syn can spread to neighboring brain regions and cause aggregation of endogenous α-syn in these regions as seeds, in a “prion-like” manner. Abundant studies in vitro and in vivo have shown that α-syn goes through a templated conformational change, propagates from the original region to neighboring regions, and eventually cause neuron degeneration in the substantia nigra and striatum. The objective of this review is to summarize the mechanisms involved in the aggregation of abnormal intracellular α-syn and its subsequent cell-to-cell transmission. According to these findings, we look forward to effective therapeutic perspectives that can block the progression of neurodegenerative diseases.
- 1 January 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (1) , 38-43
Plasma miR-126 and miR-143 as Potential Novel Biomarkers for Cerebral Atherosclerosis
- 1 January 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (1) , 38-43
Plasma miR-126 and miR-143 as Potential Novel Biomarkers for Cerebral Atherosclerosis
- 1 January 2014
- Published by Elsevier in Neuroscience Letters
- Vol. 559, 158-162
Association of RAGE gene polymorphisms with sporadic Parkinson's disease in Chinese Han population
- 1 January 2014
- Published by Elsevier in Neuroscience Letters
- Vol. 559, 158-162
Association of RAGE gene polymorphisms with sporadic Parkinson's disease in Chinese Han population